Basically Gilead is going to reap the benefit of two periods of exclusivity rather than one, correct?
John Sarbanes: “Basically Gilead is going to reap the benefit of two periods of exclusivity rather than one, correct?”
On the recordMay 15, 2019
Source
congress.govEditor's note · Context
Sarbanes highlights potential exclusivity benefits for Gilead from two drug developments.
Share
More from John Sarbanes
May 9, 2023
It's a national environmental treasure. It's a regional economic engine. It's been one of my top priorities since I've come to Congress.
May 9, 2023
Without the strong and continued investment the EPA has requested for the Chesapeake Bay Program in fiscal year 2024, the risk is we could jeopardize decades of work in collaboration towards the Bay's restoration.
Oct 17, 2023
I hope that today's hearing is the first step in continuing that legacy of strong bipartisan support for the Chesapeake Bay in this Congress.
Oct 17, 2023
We would like to thank Rep. Sarbanes for introducing this important piece of bipartisan legislation





